At a glance
| Known as | ALKS 4510 |
|---|---|
| Sponsor | Alkermes |
| Mechanism | Orexin receptor agonist |
| Stage | Phase 1 |
| Indications | Fatigue in MS · Fatigue in Parkinson's |
| Registered trials | 0 |
| Last verified | 4 Aug 2026 |
Where it stands
ALKS 4510 aims the orexin mechanism at fatigue associated with multiple sclerosis and Parkinson's disease — two conditions where debilitating fatigue is common and poorly served by existing treatments.
It sits at Phase 1 on Alkermes' own pipeline page and is not yet listed on ClinicalTrials.gov under this compound name, so there is no public trial record to read yet.
ALKS 4510 — common questions
What is ALKS 4510 for?
Fatigue associated with multiple sclerosis and Parkinson's disease, according to Alkermes' pipeline page.
Can I find the ALKS 4510 trial on ClinicalTrials.gov?
Not yet. As of the last check on 4 August 2026 it was not listed on ClinicalTrials.gov under this compound name. The only public source is Alkermes' own pipeline page.
Source
This entry was last checked against its primary source on 4 Aug 2026: https://www.alkermes.com/research-and-development/pipeline
Found something out of date? Send a correction with a primary source and it will be fixed.
Get told when this changes
One email when ALKS 4510 changes phase, reads out, or hits a regulatory milestone.
One email per real change. No tracking pixels, no list rental, one-click unsubscribe.